AVH seems to be in front of the feild in regenerative medicine by several lengths. it appears MSB has won the hearts and minds of the analysts, US based analysts. But AVH from a commercial perspective is definitely way in front.
So are we talking the eventual size of MSB markets, are they bigger than AVH, whohas the stiff competition, Which company has the most ground to cover before becoming commercial?
Not many analysts follow this sub-sector, no-body seems tofollow AVh, MSb is well known, the recognised leader in Re-generative Medicine. AVH is not recognised, the more digging, the more questions, after MSB, Israel seems to be the place to look, but so far not much has turned up that is anywhere near as advanced.
Many companies are chasing the same prize. AVhs strength appears to be the on-site harvesting of cells. its a bit hard to harvest from the inside of human organs.
It looks like nobody but a few small punters and AEF follow this company. Still looks cjeap at .14.The 500K sell at .14 might not be there very long.
AVH Price at posting:
13.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)